About Avenzoar Pharmaceuticals
Avenzoar Pharmaceuticals is a private company based in Los Angeles, California. It has reported $1,424,892 raised in two offerings on Form D since October 2019. Its chief executive is Terrance Bruggeman.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 31, 2023 | Jun 16, 2023 | $899,748of $2.9M target | 2 | $449K | Debt, OptionsRule 506(b) | Form D ↗ |
| Oct 17, 2019 | Oct 31, 2019 | $525,144of $918K target | 4 | $131K | Equity, DebtRule 506(b) | Form D ↗ |
| Total, two offerings | $1,424,892 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Avenzoar Pharmaceuticals's Form D filed Jun 16, 2023.
MC
Mark Chin
Director
SW
Shierley Widjaja
Director
SP
Stephen Pandol
Director
ME
Mouad Edderkaoui
Director
TB
Terrance Bruggeman
Chief Executive Officer and director
Earlier filings also listed William Reavey (executive officer, last listed Oct 2019) and David Kramer (executive officer, last listed Oct 2019).